)
-
Regulatory scientists actively monitoring CoRAP to anticipate implications for clients
-
Multiple chemicals supported through CoRAP substance evaluation
-
Proven track record of defense and advocacy
The ECHA community rolling action plan (CoRAP) process prioritizes the evaluation of substances in the EU/EEA over a three-year period. The aim of the evaluation is to investigate the risk posed by a chemical to human health or the environment. Priority is given to substances suspected of being of highest risk. ECHA updates CoRAP annually in March, adding new chemicals and revising timings for chemicals already listed on the plan.
Substance prioritization follows a risk-based approach to both potential hazard and exposure. Hazard information includes potential persistency, bioaccumulation and toxicity (PBT), endocrine disruption, or carcinogenicity, mutagenicity and toxicity to reproduction (CMR). Exposure potential is based on a chemical’s use and total registered volumes.
Responding to ECHA information requests
Once a chemical appears on CoRAP, a series of substance evaluation steps are set in action. You need to understand the steps in the process and the timelines to efficiently engage and comply with information requests from ECHA.
Proactively engaging with ECHA to support your chemical through CoRAP evaluation
Although substance evaluation is a formal process, registrants can engage with the evaluating Member State Competent Authority (eMSCA). Our regulatory scientists have a track record of positive engagement with ECHA to discuss scientific and technical issues related to substance evaluation. Engaging positively, early in the process, helps clarify issues and ensures any safety questions are addressed comprehensively and cost effectively.
With vast experience and insight into the substance evaluation process, our team will keep you on course with all administrative aspects of CoRAP.
Advocating for your substance
You may need to challenge or defend the substance evaluation in front of ECHA. Our team has expertise as advocates, defending the scientific and regulatory basis for risk interpretations. We can support you by defending substance evaluations to regulators in written form, by telephone and through face-to-face communications, as required.